Login to Your Account

YM's $70M Offering Capitalizes On Positive Myelofibrosis Trial

By Catherine Shaffer
Staff Writer

Monday, February 27, 2012

YM Biosciences Inc. has enjoyed a sustained boost to its stock value since reporting positive Phase I/II results for JAK/JAK2 kinase inhibitor CYT387 in December 2011.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription